Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968424 | 0.89 | CYP3A4 (0.57) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL2329005 | 0.86 | CYP3A4 (0.55) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL24411225 | 0.86 | CYP3A4 (0.55) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL29214652 | 0.84 | CYP3A4 (0.52) | CYP3A4GRM4MAOATLR8ALOX5 | |
| SCHEMBL28665368 | 0.83 | CYP3A4 (0.51) | CYP3A4GRM4MAOB | |
| SCHEMBL29214660 | 0.83 | CYP3A4 (0.51) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL13443841 | 0.80 | HTR1A (0.57) | CYP3A4APPMETPRKACG | |
| SCHEMBL3898712 | 0.79 | CYP3A4 (0.58) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL311094 | 0.79 | CYP3A4 (0.58) | CYP3A4GRM4MAOATLR8DYRK1A | |
| SCHEMBL30153587 | 0.79 | CYP3A4 (0.58) | CYP3A4GRM4MAOATLR8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510036-B1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-07-21 | — | — | EP | disclosed |